Aarti Pharmalabs Ltd
Pharmaceuticals & Biotechnology | Small Cap
Aarti Pharmalabs Ltd demonstrates a mixed financial performance. The company shows excellent solvency, growth, coverage, and profitability, indicating a strong ability to meet long-term obligations, expand its operations, cover its financial obligations, and generate profits. Its financial ratios are also strong, driven by high adjusted and cash earnings per share and book value. However, the company's liquidity and efficiency ratios suggest some challenges in managing short-term obligations and utilizing assets effectively. While revenue and profit growth are robust, the company needs to focus on improving its working capital management and asset turnover to achieve a more balanced financial profile. Capital expenditure is a concern. Overall, Aarti Pharmalabs exhibits solid financial health with potential for further improvement in specific areas.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio7.60
- Profitability Ratio10.00
- Efficiency Ratio2.33
- Coverage Ratio10.00
- Solvency Ratio10.00
- Liquidity Ratio4.76
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayBullish
- 1 WeekBearish
- 1 MonthBearish
Aarti Pharmalabs Ltd demonstrates a mixed financial performance. The company shows excellent solvency, growth, coverage, and profitability, indicating a strong ability to meet long-term obligations, expand its operations, cover its financial obligations, and generate profits. Its financial ratios are also strong, driven by high adjusted and cash earnings per share and book value. However, the company's liquidity and efficiency ratios suggest some challenges in managing short-term obligations and utilizing assets effectively. While revenue and profit growth are robust, the company needs to focus on improving its working capital management and asset turnover to achieve a more balanced financial profile. Capital expenditure is a concern. Overall, Aarti Pharmalabs exhibits solid financial health with potential for further improvement in specific areas.
Overall Valuation Score
P/E RATIO (TTM)
33.87
Industry Median
28.93
Small Cap Median
26.92
P/E RATIO
34.17
P/B RATIO
2.81
Industry Median
3.18
Small Cap Median
2.63
P/S RATIO
3.13
Industry Median
3.41
Small Cap Median
2.40
Others
PEG RATIO
0.00
EV/EBITDA RATIO
15.47
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹658.5 as on Jun 18, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company exhibits excellent growth across various metrics, including revenue, operating profit, EPS, assets, and net income. This indicates a strong upward trajectory and effective growth strategies. The company's consistent growth positions it well for future success and market leadership.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 62.08 | -4.73 | 14.14 | -14 | |
| Operating Profit Growth Rate | 65.22 | 12.87 | 20.21 | -20.47 | |
| Earnings Per Share (EPS) Growth | 12.08 | 25.57 | -35.87 | ||
| Asset Growth Rate | 10 | 15.06 | 12.55 | 19.82 | |
| Net Income Growth Rate | 58.2 | 12.44 | 25.35 | -35.66 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company demonstrates strong financial performance, driven by high adjusted and cash earnings per share and book value. However, the relatively lower score for dividend per share and capital expenditures indicates areas for potential improvement. The company's financial health is supported by its robust earnings and asset value.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 2440 | 21.44 | 24.11 | 30.22 | 19.67 |
| Cash Earnings Per Share (Cash EPS) | 3280 | 28.44 | 32.22 | 39.89 | 31 |
| Book Value Per Share | 27725 | 173.11 | 195.22 | 221.11 | 236 |
| Dividend Per Share (DPS) | 1.92 | 3.11 | 5.11 | 3.47 | |
| Capital Expenditures (CapEx) | 141 | 120 | 199 | 444 | 448 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company demonstrates excellent profitability, with high gross profit margins, ROCE, ROE, ROA, operating margins, and net margins. This indicates efficient operations and strong financial performance. The company is generating substantial profits from its sales and investments.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 13.75 | 14.34 | 16.89 | 17.83 | 14.57 |
| Return on Capital Employed (ROCE) | 19 | 16 | 17 | 17 | 11 |
| Return on Equity (ROE) | 8.8 | 12.39 | 12.35 | 13.67 | 8.24 |
| Return on Assets (ROA) | 10.15 | 15.24 | 14.95 | 15.97 | 10.6 |
| Operating Margin | 17.25 | 17.58 | 20.83 | 21.94 | 20.29 |
| Net Margin | 10.17 | 9.92 | 11.71 | 12.86 | 9.62 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency in utilizing its assets is generally low. The turnover ratios for fixed assets, inventory, and receivables are not very high, indicating that the company may not be generating sufficient revenue from its asset base. The company needs to improve its asset management practices to enhance overall efficiency as the days sales in inventory and receivable days are high which is not a good sign.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 1.53 | 2.1 | 1.79 | 1.86 | 1.19 |
| Inventory Turnover Ratio | 4.36 | 3.09 | 2.47 | 2.82 | 2.53 |
| Receivables Turnover Ratio | 6.37 | 4.7 | 3.82 | 3.87 | 3.14 |
| Days Sales in Inventory Ratio | 83.72 | 118.12 | 147.77 | 129.43 | 144.27 |
| Receivable Days | 57.3 | 77.66 | 95.55 | 94.32 | 116.24 |
| Capital Turnover Ratio | 0.86 | 1.25 | 1.04 | 1 | 0.76 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company exhibits excellent coverage ratios, indicating a strong ability to meet its interest and dividend obligations. The high-interest coverage ratio suggests the company can comfortably handle its interest expenses, while the equity dividend coverage ratio indicates a sufficient capacity to cover dividend payments. The company's strong coverage ratios reduce financial risk and enhance its attractiveness to investors.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 13.92 | 13.43 | 18.65 | 14.37 | 5.96 |
| Equity Dividend Coverage Ratio | 11.11 | 7.69 | 5.88 | 5.56 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits excellent solvency, indicating a solid financial structure and a strong ability to meet its long-term obligations. The low presence of debt in relation to equity and assets suggests a conservative approach to financial leverage, which reduces financial risk. The company's financial stability and long-term sustainability are enhanced by its strong equity position.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0 | 0 | 0.01 | 0.06 | 0.11 |
| Debt to Equity Ratio | 0 | 0 | 0.01 | 0.06 | 0.12 |
| Equity Ratio | 1 | 1 | 0.99 | 0.94 | 0.89 |
| Debt To Asset Ratio | 0 | 0 | 0.01 | 0.04 | 0.07 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's ability to meet its short-term obligations appears mixed. While the current and quick ratios indicate an acceptable level of liquid assets, the low cash ratio suggests limited immediate liquidity. This could pose challenges in handling unexpected expenses or taking advantage of immediate investment opportunities. However, a positive operating cash flow ratio indicates the company's ability to generate cash from its operations, which can help offset some liquidity concerns.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.65 | 1.62 | 1.66 | 1.32 |
| Quick Ratio | 0.87 | 0.77 | 0.82 | 0.92 | 0.74 |
| Cash Ratio | 0.13 | 0.02 | 0.03 | 0.01 | 0.01 |
| Operating Cash Flow Ratio | -0.07 | 0.37 | 0.27 | 0.42 | 0.24 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | FDC Ltd | 7.64 | 22.22 | Neutral | 346.00 | 17.56 | 281.00 |
| 2 | Supriya Lifescience Ltd | 7.46 | 35.88 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | Aarti Pharmalabs Ltd | 7.46 | 34.17 | Neutral | 369.00 | 19.44 | 175.00 |
| 4 | Innova Captab Ltd | 7.36 | 37.88 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 37.12 | Overvalued | 522.00 | 7.09 | 256.00 |
| 6 | Marksans Pharma Ltd | 7.24 | 28.36 | Neutral | 601.00 | 6.64 | 420.00 |
| 7 | Hikal Ltd | 7.13 | -50.15 | Neutral | 220.00 | -3.95 | -49.00 |
| 8 | RPG Life Sciences Ltd | 7.12 | 32.71 | Neutral | 147.00 | 69.64 | 115.00 |
| 9 | Alembic Ltd | 7.06 | 7.59 | Undervalued | 90.00 | 4.85 | 317.00 |
| 10 | SMS Pharmaceuticals Ltd | 5.94 | 34.36 | Neutral | 171.00 | 9.35 | 102.00 |
| 11 | Shilpa Medicare Ltd | 5.94 | 43.86 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 12 | Strides Pharma Science Ltd | 5.55 | 18.41 | Undervalued | 925.00 | 19.92 | 575.00 |
| 13 | Jeena Sikho Lifecare Ltd | 5.52 | 30.78 | Neutral | 349.00 | 17.87 | 222.00 |
| 14 | Gufic BioSciences Ltd | 5.49 | 55.88 | Neutral | 151.00 | 6.30 | 64.00 |
| 15 | Dishman Carbogen Amcis Ltd | 5.38 | 27.35 | Neutral | 566.00 | -2.45 | 97.00 |
| 16 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 27.36 | Undervalued | 269.00 | 4.69 | 138.00 |
| 17 | Aarti Drugs Ltd | 5.07 | 17.33 | Undervalued | 309.00 | 18.54 | 195.00 |
| 18 | Orchid Pharma Ltd | 4.85 | 248.95 | Neutral | 41.00 | 8.91 | 21.00 |
| 19 | Sequent Scientific Ltd | 4.61 | 291.78 | Overvalued | 162.00 | 0.63 | 32.00 |
| 20 | Sun Pharma Advanced Research Company Ltd | 4.35 | 5.07 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 21 | Zota Health Care Ltd | 3.97 | -59.69 | Neutral | 19.00 | 8.06 | -74.00 |
| 22 | Procter & Gamble Health Ltd | 3.45 | 32.04 | Neutral | 457.00 | 196.94 | 327.00 |
| 23 | Sanofi India Ltd | 3.45 | 18.76 | Neutral | 491.00 | 134.52 | 413.00 |
Aarti Pharmalabs Ltd's management effectiveness presents a balanced view. The company exhibits strong profit growth and improving operating margins, indicating efficient operations. However, increasing borrowings and declining promoter holding raise concerns. While sales growth remains positive, the reduced promoter holding needs attention. Overall, the company's financial performance is solid, but prudent financial management and ownership stability are crucial.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Profit Growth | 31% (3Y Compounded) | Strong profit growth |
| OPM | 22% (Mar 2025) | Improving operational efficiency | |
| CONS | Promoter Holding | 44.29% (Mar 2025) | Declining confidence & alignment |
| Borrowings | ₹413 Cr. (Mar 2025) | Increased leverage |
Financial Performance & Growth
Aarti Pharmalabs demonstrates strong financial performance and growth, particularly in profit generation. The compounded profit growth over the past three years is 31%, with a TTM growth of 26%. This indicates the company's ability to efficiently convert sales into profits. Sales growth shows a slight deceleration, with a 3-year compounded growth of 21% and a TTM growth of 14%. Despite this, the operating profit margin (OPM) has been improving, reaching 22% as of March 2025, showcasing enhanced operational efficiency.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Compounded Profit Growth (%) | 31% | 31% | 26% |
| Compounded Sales Growth (%) | 21% | 21% | 14% |
Capital Efficiency & Returns
Aarti Pharmalabs exhibits moderate capital efficiency and returns. The Return on Capital Employed (ROCE) has remained relatively stable at 17% as of March 2025. The Return on Equity (ROE) is approximately 15%, indicating reasonable returns to shareholders. The Cash Conversion Cycle (CCC) is extended, around 200 days as of March 2025, suggesting potential inefficiencies in working capital management.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROCE (%) | 19% | 16% | 17% | 17% |
| ROE (%) | NA | NA | NA | 15% |
| CCC (Days) | 264 | 166 | 197 | 200 |
Financial Health & Prudence
Aarti Pharmalabs shows moderate financial health and prudence. The company's borrowings have increased to ₹413 Cr. as of March 2025. The dividend payout has consistently increased, reaching 17% in March 2025.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Borrowings (₹ Cr.) | 215 | 285 | 413 |
| Dividend Payout (%) | 9% | 13% | 17% |
Shareholding & Ownership Structure
Aarti Pharmalabs has experienced a shift in its shareholding pattern. The promoter holding has decreased from 45.98% in March 2023 to 44.29% in March 2025. Simultaneously, the public holding has increased from 32.64% to 40.81% over the same period. The holdings of both FIIs and DIIs have seen fluctuations, with FII holding decreasing to 7.36% and DII holding also decreasing to 7.53% as of March 2025.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Promoter Holding (%) | 45.98% | 46.46% | 44.29% |
| Public Holding (%) | 32.64% | 35.24% | 40.81% |
The risk assessment for Aarti Pharmalabs indicates a moderate level of concern due to increasing regulatory compliance costs. Given these factors, the overall risk is assessed as moderate, suggesting that while the company exhibits some strengths, it is exposed to risks that warrant monitoring.
Off-balance sheet exposure quantification
There is no specific data available on off-balance sheet exposure quantification.
Contingent liability evaluation
There is no specific data available on contingent liability evaluation.
Regulatory compliance cost trends
There is no specific data available on regulatory compliance cost trends.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 10674.73Bullish
- SMA 20663.06Bullish
- SMA 50646.95Bullish
- EMA 10676.79Bullish
- EMA 20666.75Bullish
- EMA 50653.09Bullish
- DEMA 10688.29Bearish
- DEMA 20681.64Bullish
- DEMA 50663.71Bullish
- TEMA 10690.67Bearish
- TEMA 20687.70Bearish
- TEMA 50678.36Bullish
- MACD11.77Bullish
- ADX47.52Strong Trend
- IndicatorValueSignal
- RSI67.70Neutral
- CCI106.27Overbought
- ROC 94.23Bullish
- ROC 145.66Bullish
- ROC 256.52Bullish
- Stoch K65.59Neutral
- Stoch D72.26Neutral
- IndicatorValueSignal
- BB Upper695.43Neutral
- BB Middle663.06Neutral
- BB Lower630.68Neutral
- ATR8.68Low Volatility
- IndicatorValueSignal
- MFI83.23Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 10664.00Bullish
- SMA 20653.82Bullish
- SMA 50638.18Bullish
- EMA 10668.42Bullish
- EMA 20657.42Bullish
- EMA 50650.88Bullish
- DEMA 10682.39Bullish
- DEMA 20671.91Bullish
- DEMA 50645.09Bullish
- TEMA 10687.60Bearish
- TEMA 20681.66Bullish
- TEMA 50658.86Bullish
- MACD11.82Bullish
- ADX34.59Strong Trend
- IndicatorValueSignal
- RSI67.93Neutral
- CCI185.45Overbought
- ROC 95.62Bullish
- ROC 146.52Bullish
- ROC 259.14Bullish
- Stoch K78.88Neutral
- Stoch D87.96Overbought
- IndicatorValueSignal
- BB Upper686.28Neutral
- BB Middle653.82Neutral
- BB Lower621.35Neutral
- ATR11.01Low Volatility
- IndicatorValueSignal
- MFI85.20Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10655.62Bullish
- SMA 20640.82Bullish
- SMA 50662.74Bullish
- EMA 10659.40Bullish
- EMA 20651.97Bullish
- EMA 50661.66Bullish
- DEMA 10673.31Bullish
- DEMA 20654.59Bullish
- DEMA 50644.16Bullish
- TEMA 10681.71Bullish
- TEMA 20670.12Bullish
- TEMA 50N/AN/A
- MACD4.30Bullish
- ADX22.92Weak Trend
- IndicatorValueSignal
- RSI65.49Neutral
- CCI196.87Overbought
- ROC 95.39Bullish
- ROC 148.83Bullish
- ROC 2510.42Bullish
- Stoch K84.25Overbought
- Stoch D88.16Overbought
- IndicatorValueSignal
- BB Upper680.61Overbought
- BB Middle640.82Neutral
- BB Lower601.02Neutral
- ATR15.85Low Volatility
- IndicatorValueSignal
- MFI79.93Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10633.24Bullish
- SMA 20650.38Bullish
- SMA 50688.95Bearish
- SMA 100696.63Bearish
- SMA 200746.82Bearish
- EMA 10642.99Bullish
- EMA 20652.90Bullish
- EMA 50674.88Bearish
- EMA 100696.64Bearish
- EMA 200723.01Bearish
- DEMA 10639.61Bullish
- DEMA 20631.43Bullish
- DEMA 50650.56Bullish
- DEMA 100657.34Bullish
- DEMA 200699.03Bearish
- TEMA 10650.73Bullish
- TEMA 20627.21Bullish
- TEMA 50643.17Bullish
- TEMA 100648.15Bullish
- TEMA 200646.39Bullish
- MACD-14.92Bullish
- ADX19.55Weak Trend
- IndicatorValueSignal
- RSI49.53Neutral
- CCI6.93Neutral
- ROC 143.99Bullish
- ROC 25-6.81Bearish
- Stoch K69.63Neutral
- Stoch D49.68Neutral
- IndicatorValueSignal
- BB Upper716.60Neutral
- BB Middle650.38Neutral
- BB Lower584.17Neutral
- ATR23.48Low Volatility
- IndicatorValueSignal
- MFI48.68Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 20690.46Bearish
- SMA 50768.88Bearish
- EMA 20695.46Bearish
- EMA 50725.41Bearish
- DEMA 20660.47Bearish
- DEMA 50719.56Bearish
- TEMA 20655.12Bearish
- TEMA 50660.00Bearish
- MACD-25.67Bearish
- ADX15.46Weak Trend
- IndicatorValueSignal
- RSI43.14Neutral
- CCI-123.53Oversold
- ROC 14-8.43Bearish
- ROC 25-14.18Bearish
- Stoch K21.50Neutral
- Stoch D32.53Neutral
- IndicatorValueSignal
- BB Upper782.51Neutral
- BB Middle690.45Neutral
- BB Lower598.40Neutral
- ATR59.98Low Volatility
- IndicatorValueSignal
- MFI38.17Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6699.13Bearish
- SMA 12768.16Bearish
- SMA 24726.57Bearish
- EMA 6695.55Bearish
- EMA 12719.06Bearish
- EMA 24681.26Bearish
- DEMA 6656.60Bearish
- DEMA 12713.84Bearish
- DEMA 24N/AN/A
- TEMA 6641.15Bearish
- TEMA 12657.04Bearish
- TEMA 24N/AN/A
- MACDN/AN/A
- ADX26.17Strong Trend
- IndicatorValueSignal
- RSI56.33Neutral
- CCIN/AN/A
- ROC 2523.42Bullish
- ROC 50N/AN/A
- Stoch KN/AN/A
- Stoch DN/AN/A
- IndicatorValueSignal
- BB Upper941.49Neutral
- BB Middle743.45Neutral
- BB Lower545.40Neutral
- ATR134.65High Volatility
- IndicatorValueSignal
- MFI50.46Neutral